OBJECTIVE: To evaluate the safety and efficacy of Pirfenidone (PFD) in the treatment of equine corneal fibrosis using an in vitro model. METHODS: Healthy donor equine corneas were collected and used to generate primary equine corneal fibroblasts (ECFs) by growing cultures in minimal essential medium supplemented with 10% fetal bovine serum. Equine corneal myofibroblasts (ECMs), used as a model of equine corneal fibrosis, were produced by growing ECF cultures in serum-free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue viability assays and changes in ECF morphology were utilized to determine the optimal PFD dose for this in vitro model. Trypan blue viability, phase-contrast microscopy, and TUNEL assays were used to evaluate the cytotoxicity of PFD. Scratch and MTT assays were used to evaluate the effect of PFD on cellular migration and proliferation. Real-time PCR, immunoblot analysis, and immunocytochemistry were employed to determine the efficacy of PFD to inhibit ECM formation in vitro. RESULTS: Topical PFD application at 200 μg/mL successfully decreased αSMA expression when compared to the TGFβ1 only treatment group (P < 0.01). PFD application ≤ 200 μg/mL did not affect ECF phenotype or cellular viability and did not result in significant cytotoxicity. CONCLUSIONS: Pirfenidone safely and effectively inhibits TGFβ1-induced equine corneal fibrosis in vitro. In vivo studies are warranted.
OBJECTIVE: To evaluate the safety and efficacy of Pirfenidone (PFD) in the treatment of equinecorneal fibrosis using an in vitro model. METHODS: Healthy donorequine corneas were collected and used to generate primary equine corneal fibroblasts (ECFs) by growing cultures in minimal essential medium supplemented with 10% fetal bovine serum. Equine corneal myofibroblasts (ECMs), used as a model of equinecorneal fibrosis, were produced by growing ECF cultures in serum-free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue viability assays and changes in ECF morphology were utilized to determine the optimal PFD dose for this in vitro model. Trypan blue viability, phase-contrast microscopy, and TUNEL assays were used to evaluate the cytotoxicity of PFD. Scratch and MTT assays were used to evaluate the effect of PFD on cellular migration and proliferation. Real-time PCR, immunoblot analysis, and immunocytochemistry were employed to determine the efficacy of PFD to inhibit ECM formation in vitro. RESULTS: Topical PFD application at 200 μg/mL successfully decreased αSMA expression when compared to the TGFβ1 only treatment group (P < 0.01). PFD application ≤ 200 μg/mL did not affect ECF phenotype or cellular viability and did not result in significant cytotoxicity. CONCLUSIONS:Pirfenidone safely and effectively inhibits TGFβ1-induced equinecorneal fibrosis in vitro. In vivo studies are warranted.
Authors: Marcelo V Netto; Rajiv R Mohan; Renato Ambrósio; Audrey E K Hutcheon; James D Zieske; Steven E Wilson Journal: Cornea Date: 2005-07 Impact factor: 2.651
Authors: A Di Sario; E Bendia; G Macarri; C Candelaresi; S Taffetani; M Marzioni; A Omenetti; S De Minicis; L Trozzi; A Benedetti Journal: Dig Liver Dis Date: 2004-11 Impact factor: 4.088
Authors: M F Cordeiro; A Mead; R R Ali; R A Alexander; S Murray; C Chen; C York-Defalco; N M Dean; G S Schultz; P T Khaw Journal: Gene Ther Date: 2003-01 Impact factor: 5.250
Authors: Todd L Marlo; Elizabeth A Giuliano; Ratnakar Tripathi; Ajay Sharma; Rajiv R Mohan Journal: Vet Ophthalmol Date: 2017-07-06 Impact factor: 1.644
Authors: Allison A Fuchs; Praveen K Balne; Elizabeth A Giuliano; Nishant R Sinha; Rajiv R Mohan Journal: PLoS One Date: 2022-01-10 Impact factor: 3.240